logo

Alnylam Pharmaceuticals Inc. (ALNY)



Trade ALNY now with
  Date
  Headline
2/7/2019 5:11:25 PM Alnylam Pharma Q4 Loss/share $2.09 Vs. Loss $1.48 Year Ago
2/6/2019 5:02:43 PM Alnylam Reports Publication Of Phase 1 Givosiran Data In The New England Journal Of Medicine
1/23/2019 8:01:15 AM CAMP4 Therapeutics Announces Rare Disease Research Collaboration With Alnylam
1/21/2019 3:11:34 AM Alnylam Pharma And Medison Pharma Partner To Commercialize RNAi Therapeutics In Israel
1/14/2019 9:25:08 PM Alnylam Pharma Prices Underwritten Public Offering Of 5 Mln Shares At $77.50/shr
1/14/2019 4:07:33 PM Alnylam Pharmaceuticals Announces Proposed Public Offering Of Common Stock
1/7/2019 8:06:51 AM Alnylam Says Maintained Strong Balance Sheet With Unaudited Year-End Cash And Investments Balance Of About $1.1 Bln
12/10/2018 2:02:07 AM Alnylam Resolves All Litigation Worldwide With Silence Therapeutics
12/6/2018 7:05:19 AM Alnylam Pharma Plans To Discuss Its Pipeline Goals For 2019 At R&D Day
11/26/2018 7:01:38 AM Vir Biotechnology, Alnylam Pharmaceuticals Begin Phase 1/2 Study Of VIR-2218
11/7/2018 8:04:39 AM Alnylam Pharma Q3 Non-GAAP Net Loss $157.3 Mln Or $1.56/shr Vs.net Loss $97.0 Mln Or $1.06/shr Prior Year
10/29/2018 7:32:59 AM Invitae Corp Expands Partnership With Alnylam Pharma To Provide Access To Genetic Testing For Primary Hyperoxaluria